Financials Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-07 pm EDT 5-day change 1st Jan Change
42.93 USD -3.90% Intraday chart for Exact Sciences Corporation -5.54% -41.97%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13,616 21,070 13,412 8,797 13,379 7,922 - -
Enterprise Value (EV) 1 14,120 20,573 14,561 10,401 14,916 9,650 9,237 8,803
P/E ratio -145 x -23.6 x -22.4 x -14 x -65.5 x -41 x -437 x 56.9 x
Yield - - - - - - - -
Capitalization / Revenue 15.5 x 14.1 x 7.59 x 4.22 x 5.35 x 2.8 x 2.46 x 2.19 x
EV / Revenue 16.1 x 13.8 x 8.24 x 4.99 x 5.97 x 3.41 x 2.87 x 2.43 x
EV / EBITDA -117 x 789 x -77.4 x -72.5 x 68.2 x 29.2 x 18.3 x 13.1 x
EV / FCF -49.2 x 285 x -61.2 x -23.7 x 467 x 386 x 27.5 x 16.4 x
FCF Yield -2.03% 0.35% -1.63% -4.21% 0.21% 0.26% 3.64% 6.09%
Price to Book 5.97 x 7.09 x 3.94 x 2.87 x 4.27 x 2.38 x 2.17 x 1.92 x
Nbr of stocks (in thousands) 147,232 159,030 172,319 177,684 180,850 184,530 - -
Reference price 2 92.48 132.5 77.83 49.51 73.98 42.93 42.93 42.93
Announcement Date 2/11/20 2/16/21 2/22/22 2/21/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 876.3 1,491 1,767 2,084 2,500 2,831 3,221 3,619
EBITDA 1 -120.7 26.08 -188.1 -143.4 218.8 330.5 505 669.9
EBIT 1 -170.9 -137.3 -599.4 -580 -259.1 -186.6 -12.14 123.7
Operating Margin -19.51% -9.21% -33.92% -27.83% -10.36% -6.59% -0.38% 3.42%
Earnings before Tax (EBT) 1 -268.9 -857.1 -842.5 -632.6 -201.7 -179 -6.458 134.1
Net income 1 -83.99 -848.5 -595.6 -623.5 -204.1 -194.1 -25.66 118.2
Net margin -9.59% -56.9% -33.71% -29.91% -8.17% -6.86% -0.8% 3.26%
EPS 2 -0.6400 -5.610 -3.480 -3.540 -1.130 -1.048 -0.0982 0.7549
Free Cash Flow 1 -286.8 72.13 -238 -438 31.93 25 336.3 536
FCF margin -32.73% 4.84% -13.47% -21.02% 1.28% 0.88% 10.44% 14.81%
FCF Conversion (EBITDA) - 276.6% - - 14.59% 7.56% 66.59% 80.01%
FCF Conversion (Net income) - - - - - - - 453.64%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/11/20 2/16/21 2/22/22 2/21/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 473.8 486.6 521.6 523.1 553 602.4 622.1 628.3 646.9 637.5 691 731.4 771.7 734.4 787.5
EBITDA 1 -122.2 -89.82 -45.77 -13.04 4.934 45.91 66.85 56.28 49.71 39.2 68.63 104 121.8 80.8 121
EBIT 1 -222.2 -202.9 -162.1 -119.9 -95.34 -65.73 -72.1 -68.07 -70.93 -88.28 -57.11 -22.38 -8.308 -52.97 -11.43
Operating Margin -46.9% -41.71% -31.08% -22.93% -17.24% -10.91% -11.59% -10.83% -10.97% -13.85% -8.26% -3.06% -1.08% -7.21% -1.45%
Earnings before Tax (EBT) 1 -224.9 -183 -167.8 -151.9 -129.9 -72.48 -79.92 1.043 -50.38 -108.4 -55.51 -19.16 -8.398 -53.83 -9.587
Net income 1 -220.6 -180.9 -166.1 -148.8 -127.7 -74.15 -81.03 0.794 -49.77 -110.2 -57.77 -24.36 -8.086 -53.52 -14.61
Net margin -46.56% -37.19% -31.83% -28.44% -23.1% -12.31% -13.02% 0.13% -7.69% -17.29% -8.36% -3.33% -1.05% -7.29% -1.86%
EPS 2 -1.280 -1.040 -0.9400 -0.8400 -0.7200 -0.4200 -0.4500 - -0.2700 -0.6000 -0.3108 -0.1363 -0.0365 -0.2320 -0.0503
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/22/22 4/26/22 8/2/22 11/3/22 2/21/23 5/9/23 8/1/23 11/1/23 2/21/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 504 - 1,150 1,604 1,537 1,728 1,315 881
Net Cash position 1 - 497 - - - - - -
Leverage (Debt/EBITDA) -4.176 x - -6.114 x -11.19 x 7.024 x 5.229 x 2.604 x 1.316 x
Free Cash Flow 1 -287 72.1 -238 -438 31.9 25 336 536
ROE (net income / shareholders' equity) -5.66% -33.2% -21.2% -18.4% -9.08% -4.25% 0.54% 5.07%
ROA (Net income/ Total Assets) -3.34% -20.1% -10.3% -9.16% -4.42% -3.1% -0.6% 1.2%
Assets 1 2,515 4,215 5,805 6,810 4,614 6,262 4,277 9,846
Book Value Per Share 2 15.50 18.70 19.80 17.30 17.30 18.00 19.70 22.40
Cash Flow per Share 2 -0.8800 0.8200 -0.6000 -1.270 0.8700 1.350 2.070 -
Capex 1 172 64.4 136 214 124 150 158 163
Capex / Sales 19.61% 4.31% 7.68% 10.29% 4.97% 5.31% 4.91% 4.51%
Announcement Date 2/11/20 2/16/21 2/22/22 2/21/23 2/21/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
42.93 USD
Average target price
84.86 USD
Spread / Average Target
+97.67%
Consensus
  1. Stock Market
  2. Equities
  3. EXAS Stock
  4. Financials Exact Sciences Corporation